Epalrestat- An Aldose Reductase Inhibitor

India leads the world with largest number of diabetic subjects earning the dubious distinction of being termed the diabetes capital of the world . Diabetic peripheral neuropathy developed in the majority of poorly controlled, diabetic patients as a late complication of diabetes. It is therefore of paramount importance to treat diabetic neuropathies appropriately as 50-60% of diabetic populations may progress to suffer from serious life threatening complications. Epalrestat is currently the only Aldose Reductase Inhibitor approved to treat subjective and objective symptoms of Diabetic Neuropathy. This book,provides how, Epalrestat 150 mg SR treatment showed clinically and statistically significant improvements in MNDS Score,Pressure threshold,and symptoms of peripheral neuropathy such as spontaneous pain,numbness in upper and lower limbs when compared with Epalrestat 50 mg IR tablet. The analysis should helps all the Medical Professionals Specially diabetologist and all diabetic patients whose need is to either prevent or treat neuropathy, a condition with pain filled life.

Autorentext

Dr. Sachin Devendrarao Shende, MBBS.MD.(Pharmacology) Govt. Medical College Aurangabad, Maharashtra., India.